The Russian Direct Investment Fund announced on January 21 that the Hungarian National Institute of Pharmacy and Nutrition (OGYEI) has registered the Russian coronavirus vaccine “Sputnik V”.
According to a report by the Russian Satellite News Agency on the 21st, the announcement of the Russian Direct Investment Fund pointed out that “The Russian Direct Investment Fund announced that the Russian coronavirus vaccine ‘Sputnik V’ has been registered by the Hungarian National Institute of Pharmacy and Nutrition.” Hungary also became the first EU country to officially approve the use of “Sputnik V” in its territory.
The Russian Satellite News Agency reported that after a comprehensive evaluation of the clinical trial data of this vaccine in Russia, Hungarian experts registered the vaccine within the framework of emergency use authorization.
The announcement quoted Dmitriev, general manager of the Russian Direct Investment Fund, as saying, “Hungary is the first EU country to affirm the advantages of the Russian vaccine ‘Sputnik V’ and approve the use of the vaccine in its territory.
It was an important decision that demonstrated the high level of evaluation of the safety and efficacy of this vaccine by Hungarian partners.”
Russia’s first coronavirus vaccine “Sputnik V” is a human adenovirus vector vaccine jointly developed by the Russian-Malaya National Center for Epidemiology and Microbiology and the Russian Direct Investment Fund.
It adopts two doses of vaccination procedures, with Ad26 and Ad5 as vectors, with three weeks of inoculation intervals.
The Russian Direct Investment Fund announced earlier that the effectiveness of Sputnik V in preventing COVID-19 infection was 91.4% and 100% to prevent severe COVID-19.
Currently, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan have registered Sputnik V through the accelerated registration process